<DOC>
	<DOCNO>NCT02251288</DOCNO>
	<brief_summary>A phase I prospective , randomize study healthy adult subject single center . Adult subject age 18 47 year meet enrollment criterion choose participate subject receive inactivate vaccine follow live vaccine boost 4 week ( Group 1 ) , 12 week ( Group 2 ) , 24 week ( Group 3 ) , observational group ( Group 4 ) schedule booster dose serve backup dropout three group . A fifth group receive two intramuscular dos adjuvanted H7N9 pIIV separate four week .</brief_summary>
	<brief_title>A Phase I Study Priming With Inactivated A/H7N9 Influenza Virus Vaccine With Without MF59 Adjuvant Followed Live Attenuated A/H7N9 Influenza Virus Vaccine</brief_title>
	<detailed_description>The study conduct Phase I prospective , randomize study healthy adult subject single center . Adult subject age 18 47 year meet enrollment criterion choose participate subject receive unadjuvanted adjuvanted H7H9 pIIV vaccine follow live vaccine boost 4 week ( Group 1 , n=24 ) , 12 week ( Group 2 , n=24 ) , 24 week ( Group 3 , n=24 ) , observational group ( Group 4 , n=16 ) schedule booster dose serve backup dropout three group . Within group , subject randomized 1:1 ratio receive single dose either unadjuvanted H7N9 pIIV 15 mcg ( Subgroup A ) , vaccine adjuvanted oil-in-water emulsion , MF59 , ( Subgroup B ) deliver intramuscularly . Finally , fifth group ( Group 5 , n=12 ) receive two intramuscular dos adjuvanted H7N9 pIIV separate four week . The total duration study participation subject approximately 13 month . Recruitment , enrollment administration study product suspend one follow occurs clinical research laboratory clinical site : least two respiratory culture PCR assay determine positive influenza least 10 % diagnostic test ( rapid test , respiratory culture PCR assay ) perform influenza positive two consecutive week clinical research laboratory clinical site . Recruitment , enrollment administration study product may resume 2 week without signal influenza still circulate community , define measure indicate start influenza season ( i.e. , less 2 respiratory culture PCR assay determine positive influenza le 10 % diagnostic test perform influenza positive result ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Provide write informed consent prior initiation study procedure , include future use specimen . Are able understand comply plan study procedure available study visit . Are male nonpregnant , nonbreastfeeding female , 18 47 year old , inclusive . Are good health , determine medical history , target physical examination ensure exist medical diagnosis condition ( except exclusionary ) stable . Note : Stable chronic medical condition change prescription medication , dose , frequency medication last 3 month ( define 90 day ) health outcome specific disease consider within acceptable limit last 6 month ( define 180 day ) . Any change due change health care provider , insurance company etc. , do financial reason , long class medication , consider violation inclusion criterion . Any change prescription medication due improvement disease outcome , determine site principal investigator appropriate subinvestigator , consider violation inclusion criterion . Subjects may chronic need ( prn ) medication , opinion site principal investigator appropriate subinvestigator , pose additional risk subject safety assessment reactogenicity immunogenicity . Note : Topical , nasal , inhaled medication ( exception steroid outline Subject Exclusion Criteria ( see Section 5.2 ) ) , vitamin , contraceptive permit . Oral temperature le 100.4 degree F Pulse 55 100 bpm , inclusive . Systolic blood pressure 90 140 mm Hg , inclusive . Diastolic blood pressure 55 90 mm Hg , inclusive . Women childbearing potential sexual relationship men must use acceptable method contraception 30 day prior pIIV administration 90 day last study vaccination . Note : Not sterilize via tubal ligation , bilateral oophorectomy hysterectomy still menstruate &lt; 1 year last menses menopausal ) . Includes , limit , abstinence intercourse male partner , monogamous relationship vasectomize partner , male condom use applied spermicide , intrauterine device , license hormonal method , use highly effective method contraception minimum 30 day prior study product exposure agree practice highly effective contraception duration study product exposure , include 3 month ( define 90 day ) last study vaccination . A highly effective method contraception define one result low failure rate ( i.e. , less 1 percent per year ) use consistently correctly . Female subject childbearing potential must negative urine serum pregnancy test within 24 hour prior study vaccination . Have acute illness within 72 hour prior study vaccination . Any medical disease condition , opinion investigator , contraindication study participation . Note : Includes medical disease condition would place subject unacceptable risk injury , render unable meet requirement protocol , may interfere evaluation response successful completion study . Have history significant acute chronic medical condition need chronic medication , opinion investigator , interfere immunogenicity affect safety . Note : Chronic medical condition medical condition persist 3 month ( define 90 day ) long Have immunosuppression take systemic immunosuppressant result underlie illness treatment . Diagnosis asthma reactive airway disease within past 2 year . History surgical splenectomy . Use anticancer chemotherapy radiation therapy ( cytotoxic ) within 36 month prior vaccination . Have know active neoplastic disease history hematologic malignancy . Have know hepatitis B hepatitis C infection . Have know hypersensitivity allergy egg , egg chicken protein , squalenebased adjuvant , component study vaccine . Known allergy intolerance oseltamivir . Have history severe reaction follow previous immunization license unlicensed influenza virus vaccine . Have history GuillainBarr√© Syndrome . Have history neuralgia , paresthesia , neuritis , convulsion , encephalomyelitis within 90 day prior study vaccination . Have history autoimmune disease . Note : Including , limited , neuroinflammatory disease , vasculitis , clot disorder , dermatitis , arthritis , thyroiditis , muscle , liver , kidney disease . Have history alcohol drug abuse within 5 year prior study vaccination . Have diagnosis , current past , schizophrenia , bipolar disease , psychiatric diagnosis may interfere subject compliance safety evaluation . Have hospitalize psychiatric illness , history suicide attempt , confinement danger self others within 10 year prior study vaccination . Have take oral parenteral corticosteroid dose within 30 day prior study vaccination . Chronic use ( defined daily use &gt; 7days within 30 day prior study vaccination ) inhale medication , include inhaled corticosteroid . Received licensed live vaccine within 30 day prior pIIV vaccination . This inclusive license seasonal influenza vaccine . Received licensed inactivated vaccine within 14 day prior pIIV vaccination . This inclusive license seasonal influenza vaccine . Planned receipt vaccine first study vaccination followup visit approximately 56 day second study vaccination . This inclusive license seasonal influenza vaccine Received immunoglobulin blood product ( exception Rho D immunoglobulin ) within 90 day prior study vaccination . Received experimental agent within 30 day prior pIIV administration plan receipt experimental agent within 90 day pLAIV administration . Note : Includes vaccine , drug , biologic , device , blood product , medication . Plans enroll another clinical trial could interfere safety assessment investigational product time study period . Note : Includes trial study interven tion drug , biologic , device Prior participation clinical trial influenza A/H7 vaccine history A/H7 actual potential exposure infection prior first study vaccination . Note : Documented receipt placebo trial exclusionary Plan travel outside U.S. ( continental U.S. , Hawaii Alaska ) time first study vaccination 56 day second study vaccination . Positive screening pregnancy test evidence pregnancy.Female subject breastfeed plan breastfeed give time first study vaccination 30 day last study vaccination . Seropositive H7N9 influenza A virus ( serum HAI titer &gt; 1:8 ) screening period prior first study vaccination . Positive urine drug screen opiates cocaine time checkin period confinement . Positive ELISA confirmatory Western blot test human immunodeficiency virus1 ( HIV1 ) screen period prior vaccination . Current smoker unwilling stop smoking period confinement . A nicotine patch period confinement may offer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>February 9, 2017</verification_date>
	<keyword>H7N9 pandemic</keyword>
	<keyword>inactivate influenza vaccine ( pIIV )</keyword>
	<keyword>live attenuate influenza vaccine ( pLAIV )</keyword>
	<keyword>MF59 adjuvant</keyword>
</DOC>